Friday, 16 October 2026European Markets

AVANTIUM Stock Was 14.54% Up Today

Loading stream...

(VIANEWS) - The Market ended the session with AVANTIUM (AVTX.AS) rising 14.54% to €2.56 on Wednesday, following the last session's downward trend. AEX-Index rose 0.6% to €915.68, following the last session's downward trend on what was a somewhat up trend exchanging session today.

AVANTIUM's last close was €2.24, 42.5% under its 52-week high of €3.89.

About AVANTIUM

Avantium N.V., a chemical technology company, develops and commercializes renewable chemistry solutions in the Netherlands. The company operates through three segments: Avantium R&D Solutions, Avantium Renewable Chemistries, and Avantium Renewable Polymers. It offers furandicarboxylic acid, a building block for polyethylene furanoate (PEF); and PEF, a plant-based recyclable plastic for use as packaging material. The company also provides catalyst testing systems, including Flowrence that provides catalyst testing and adsorbents. In addition, it offers R&D system and refinery catalyst testing services. Further, the company develops ray technology to produce mono-ethylene glycol from industrial sugars; and dawn technology which converts non-food plant-based feedstock to industrial sugars and lignin. Additionally, it produces polyesters using plantMEG. The company was founded in 2000 and is headquartered in Amsterdam, the Netherlands.

Earnings Per Share

As for profitability, AVANTIUM has a trailing twelve months EPS of €-0.47.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -36.88%.

Volatility

AVANTIUM's last week, last month's, and last quarter's current intraday variation average was 5.95%, 1.46%, and 2.78%.

AVANTIUM's highest amplitude of average volatility was 5.95% (last week), 3.04% (last month), and 2.78% (last quarter).

Revenue Growth

Year-on-year quarterly revenue growth grew by 23.4%, now sitting on 21.4M for the twelve trailing months.

Volume

Today's last reported volume for AVANTIUM is 1948800 which is 476.88% above its average volume of 337817.

More news about AVANTIUM (AVTX.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com